Arvinas Inc (NASDAQ:ARVN) — Market Cap & Net Worth
Market Cap & Net Worth: Arvinas Inc (ARVN)
Arvinas Inc (NASDAQ:ARVN) has a market capitalization of $483.24 Million ($483.24 Million) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12627 globally and #3072 in its home market, demonstrating a 0.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arvinas Inc's stock price $7.49 by its total outstanding shares 64517472 (64.52 Million). Review Arvinas Inc (ARVN) total liabilities to assess the company's total debt and financial obligations.
Arvinas Inc Market Cap History: 2018 to 2026
Arvinas Inc's market capitalization history from 2018 to 2026. Data shows change from $829.05 Million to $483.24 Million (-9.40% CAGR).
Index Memberships
Arvinas Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.02% | #332 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.00% | #1224 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.03% | #183 of 263 |
Weight: Arvinas Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arvinas Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arvinas Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.91x
Arvinas Inc's market cap is 2.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $829.05 Million | $14.32 Million | -$41.48 Million | 57.88x | N/A |
| 2019 | $2.65 Billion | $42.98 Million | -$62.13 Million | 61.69x | N/A |
| 2020 | $5.48 Billion | $21.80 Million | -$111.79 Million | 251.33x | N/A |
| 2021 | $5.30 Billion | $46.70 Million | -$183.20 Million | 113.48x | N/A |
| 2022 | $2.21 Billion | $131.40 Million | -$271.90 Million | 16.80x | N/A |
| 2023 | $2.66 Billion | $78.50 Million | -$367.30 Million | 33.83x | N/A |
| 2024 | $1.24 Billion | $263.40 Million | -$198.90 Million | 4.70x | N/A |
| 2025 | $765.18 Million | $262.60 Million | -$80.80 Million | 2.91x | N/A |
Competitor Companies of ARVN by Market Capitalization
Companies near Arvinas Inc in the global market cap rankings as of June 16, 2026.
Key companies related to Arvinas Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Arvinas Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Arvinas Inc's market cap moved from $829.05 Million to $ 483.24 Million, with a yearly change of -9.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $483.24 Million | -36.85% |
| 2025 | $765.18 Million | -38.13% |
| 2024 | $1.24 Billion | -53.43% |
| 2023 | $2.66 Billion | +20.32% |
| 2022 | $2.21 Billion | -58.35% |
| 2021 | $5.30 Billion | -3.29% |
| 2020 | $5.48 Billion | +106.69% |
| 2019 | $2.65 Billion | +219.77% |
| 2018 | $829.05 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Arvinas Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $483.24 Million USD |
| MoneyControl | $483.24 Million USD |
| MarketWatch | $483.24 Million USD |
| marketcap.company | $483.24 Million USD |
| Reuters | $483.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more